Ligand Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ligand Pharmaceuticals (LGND).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$302Upside to Avg. PT-0.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 25, 2026	Barclays	Glen Santangelo	Initiate	Overweight	$345
Sep 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$358
Sep 23, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$390→$397
Aug 14, 2026	Leerink Partners	David Risinger	Initiate	Outperform	$330
Aug 7, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$340→$345
Aug 6, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$289→$358
Aug 3, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$285→$326
Jul 21, 2026	Citigroup	Yigal Nochomovitz	Reinstates	Buy	$387
Jul 15, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$262→$340
Jul 9, 2026	B of A Securities	Jason Zemansky	PT Raise	Buy	$266→$388
Jul 8, 2026	Stifel	Annabel Samimy	PT Raise	Buy	$255→$332
May 8, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$252→$262
Apr 30, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$243→$289
Apr 28, 2026	RBC Capital	Douglas Miehm	PT Raise	Outperform	$235→$252
Apr 15, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$276→$282
Apr 14, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$239→$243
Mar 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$270→$276
Mar 11, 2026	B of A Securities	Jason Zemansky	Initiate	Buy	$244
Feb 27, 2026	Oppenheimer	Trevor Allred	PT Raise	Outperform	$275→$277
Feb 24, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$231→$239

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform rating and announces Price Target of $330.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $340 to $345.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $289 to $358.

Benzinga Newsdesk

Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

PRO
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

PRO
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

PRO
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

PRO
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

PRO
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

People Also Watch

People Also Watch

Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

PROHC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

PROCitigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

PROLeerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

PRORBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

PROHC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345

PRO
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target

PRO
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

PRO
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330

PRO
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345

PRO
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358